Overview of Scopamin Plus

Property	Description
Active Ingredients	Hyoscine Butylbromide, Acetaminophen (Paracetamol)
Form	Oral Tablet (Fixed-Dose Combination)
Pharmacological Class	Antispasmodic-Analgesic Combination
General Purpose	Relief of Spasmodic Pain and Cramps
Origin	Semi-synthetic and Synthetic

Scopamin Plus is defined as a specialized fixed-dose combination product, typically formulated as an oral tablet. This medicine belongs to the pharmacological group known as an Antispasmodic-Analgesic Combination. The inclusion of two active compounds in a single pill is a differentiating feature, reflecting a therapeutic strategy clinically recognized for managing pain where muscle spasm is the root cause. This dual composition is engineered to maximize convenience and ensure simultaneous action against both the muscle contraction and the resulting discomfort.

Scopamin Plus Composition and Origin

The efficacy of Scopamin Plus is founded on the complementary actions of its two key ingredients: Hyoscine Butylbromide and Acetaminophen (Paracetamol). The antispasmodic component, Hyoscine Butylbromide, is chemically a semi-synthetic derivative of a naturally occurring alkaloid, developed specifically to act peripherally on internal smooth muscles. The secondary component, Acetaminophen, is a fully synthetic non-opioid compound. This pairing is an established approach, and the formulation is recognized for its combined therapeutic benefit over single-agent alternatives. This distinction highlights the product's positioning as a targeted solution rather than a general-purpose analgesic.

What is the General Purpose of Scopamin Plus?

The essential purpose of Scopamin Plus is to provide comprehensive, targeted relief for acute spasmodic pain episodes. A typical use scenario involves sudden, intense discomfort arising from involuntary muscle contraction, such as abdominal cramping. The medicine is specifically designed to manage the debilitating sensation of internal cramping by addressing both the underlying spasm and the accompanying pain simultaneously. The overall therapeutic goal is to rapidly mitigate the intensity and duration of the cramping episode, maintaining an educational, factual, and patient-oriented focus.

What side effects are possible with Scopamin Plus?

Possible side effects and safety information

This section describes the officially documented adverse reactions and safety characteristics of the medicine, categorized according to government regulatory standards. The safety profile is defined by the known risks of its two active components: Hyoscine Butylbromide and Acetaminophen (Paracetamol).

Adverse Reactions by Frequency

Adverse reactions are classified based on their probability of occurrence as stated in regulatory labels:

Common (ge 1/100): Includes dry mouth, an effect associated with the anticholinergic component.
Uncommon (ge 1/1,000): Includes dyshidrosis (abnormal sweating) and various skin reactions like urticaria and pruritus.
Rare (ge 1/10,000): Includes tachycardia (increased heart rate) and urinary retention.
Not Known (Cannot be estimated): Includes severe reactions such as anaphylactic shock and acute liver failure.

System-Organ Classes and Serious Reactions

Officially documented adverse effects span multiple body systems. Effects on the Eye Disorders class include visual disturbances and accommodation disorders. Cardiac Disorders may include palpitations. The Hepatobiliary Disorders class is significant due to the risk of dose-dependent hepatotoxicity from Acetaminophen. The Immune System and Skin and Subcutaneous Tissue Disorders classes encompass the potential for serious events, including severe cutaneous adverse reactions (SCARs).

Safety Constraints and Special Populations

Regulatory documents stipulate that the medicine should not be used in individuals with severe hepatic impairment due to the risk of Acetaminophen toxicity. Use is also officially restricted in patients with narrow-angle glaucoma, gastrointestinal/urinary tract mechanical obstruction, megacolon, and myasthenia gravis. Furthermore, concomitant use with other anticholinergic agents carries a documented increased risk of severe anticholinergic side effects. The risk of hepatotoxicity is officially documented as being associated with cumulative dose and duration of exposure.

Overdose and Emergency Response

Overdose and When to Seek Help — Official Regulatory Information

IMMEDIATE MEDICAL ATTENTION IS MANDATORY for any suspected overdose, even if initial symptoms are mild or absent. Overdose of this combination product presents distinct toxicological risks linked to both active components: Acetaminophen (Paracetamol) and Hyoscine Butylbromide (anticholinergic).

Overdose Component	Documented Manifestations
Acetaminophen	Initial symptoms may include nausea, vomiting, abdominal pain, and pallor. The critical danger is delayed hepatotoxicity (irreversible liver damage), which may lead to metabolic acidosis, hepatic encephalopathy, coma, and death. Clinical signs of severe liver damage may not appear until 2 to 4 days after ingestion.
Hyoscine Butylbromide	Symptoms include severe anticholinergic effects, such as tachycardia (fast heart rate), dry mouth, urinary retention, and CNS effects (e.g., confusion, delirium, excitation).

Regulatory Mandates and Procedures

The most critical action is to contact a Poison Control Center or seek emergency medical attention immediately for any suspected overdose. The risk of hepatotoxicity is notably increased in individuals with chronic alcoholism or malnutrition. The specific antidote for Acetaminophen overdose is N-acetylcysteine (NAC), which is most effective if treatment begins within the first eight to ten hours following ingestion. Hospital monitoring, including serial measurements of plasma Acetaminophen levels, is required to guide life-saving treatment.

Therapeutic Uses of Scopamin Plus

Main Uses and Therapeutic Action

Scopamin Plus is a fixed-dose combination medication formulated to address gastrointestinal and genitourinary discomfort. It combines two active agents that work through different mechanisms to provide relief from pain associated with smooth muscle spasms.

Relief of Spasms and Cramps

The primary use of this medication is the management of acute spasms in the digestive tract. It is frequently utilized for conditions involving:

Stomach and intestinal cramps: It helps relax the smooth muscles of the gastrointestinal tract, which can become overactive or cramped due to various functional disorders.
Biliary colic: It is used to alleviate pain resulting from spasms in the bile ducts.
Genitourinary spasms: The medication is indicated for the relief of cramping in the urinary tract and for the management of spasmodic pain associated with the female reproductive system, such as painful menstruation (dysmenorrhea).

Pain Management

Unlike medications that only target the muscle contraction, Scopamin Plus contains an analgesic component. This allows the medication to treat both the underlying cause of the discomfort—the muscle spasm—and the sensation of pain itself. This dual action is particularly beneficial for moderate to severe cramping where smooth muscle relaxation alone may not provide sufficient relief.

Benefits of Combination Therapy

The integration of an antispasmodic and an analgesic in a single tablet offers several therapeutic advantages:

Targeted Relaxation: It acts directly on the localized site of the spasm to reduce muscle tension.
Comprehensive Symptom Control: By addressing both the physical contraction and the pain signals, it provides a broader scope of relief for abdominal and pelvic complaints.
Functional Support: By reducing spasm-induced pain, the medication can help restore more normalized movement within the affected organ systems.

Regulatory References

Indonesia BPOM Assessment Report

Eligibility and Restrictions for Use

Scopamin Plus is prohibited for use in patients who have certain pre-existing medical conditions or documented sensitivities, as mandated by regulatory documents.

Contraindicated Populations (Must Not Use)

Hypersensitivity: Individuals with a known allergy to Hyoscine (Scopolamine), Paracetamol, other belladonna alkaloids, or any component of the formulation.
Glaucoma: Patients diagnosed with angle-closure glaucoma.
Obstructive Conditions: Those with mechanical stenosis of the gastrointestinal tract, paralytic or obstructive ileus, intestinal atony, megacolon, or prostatic hypertrophy with urinary retention.
Other Conditions: Patients with myasthenia gravis or pathological tachyarrhythmia.

Restricted or Cautionary Use

Age-Related Rules: The medicine is generally not suitable for children under 10 or 12 years of age, depending on the specific product labeling, as safety and efficacy have not been fully established in younger populations.
Physiological Status: Use is generally not recommended during pregnancy or lactation due to insufficient safety data or the transfer of components into breast milk.
Organ Function: Use requires caution and medical supervision in patients with impaired hepatic or renal function, and the dosage may need to be reduced. The blood count and organ function may require monitoring during prolonged treatment.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of Scopamin Plus is defined by the properties of its two active components. Regulatory documentation establishes several critical restrictions, primarily concerning the risk of additive effects and potential toxicity.

Contraindicated Combinations and Toxicity Risk

The co-administration of any other medicine containing Acetaminophen (Paracetamol) is strictly prohibited to avoid exceeding the maximum daily dose, which carries a high risk of severe liver damage (hepatotoxicity). This toxicity risk is also significantly increased when the medicine is combined with chronic high alcohol consumption (three or more drinks per day) or with certain hepatic enzyme inducers, such as Phenobarbital or Isoniazid.

Pharmacodynamic and Exposure Interactions

Due to the Hyoscine Butylbromide component, co-administration with other anticholinergic agents (e.g., certain antidepressants or antihistamines) may lead to an intensification of anticholinergic effects. Conversely, Dopamine Antagonists (like Metoclopramide) may cause a diminution of the drug's effect on gastrointestinal motility.

Exposure of the Acetaminophen component may be altered by other agents. Cholestyramine is documented to reduce its absorption, potentially requiring a separation of administration time. Conversely, the Acetaminophen component may amplify the effect of oral anticoagulants like Warfarin upon regular daily use.

Mechanism of Action

Visceral Smooth Muscle Relaxation (Spasmolysis)

This mechanism involves the peripheral action of Hyoscine Butylbromide, which functions as a competitive antagonist at Muscarinic Acetylcholine Receptors (M1, M2, and M3) on smooth muscle cells. The drug blocks the signal from Acetylcholine, preventing the necessary intracellular calcium influx that sustains muscle tone. This engagement with the Parasympathetic Autonomic Nervous System leads to the physiological outcome of visceral smooth muscle relaxation, resulting in the reduction of excessive tension.

Central Signal Modulation (Antinociception)

The second component, the analgesic Acetaminophen (Paracetamol), acts predominantly within the Central Nervous System (CNS) by inhibiting the Cyclooxygenase (COX) pathway, thereby reducing the synthesis of inflammatory mediators like Prostaglandin E2 ( PGE2). This central enzymatic inhibition contributes to central antinociception. The mechanism is further supported by a metabolite that modulates the endocannabinoid reuptake system, collectively influencing central nociceptive signaling pathways.

Dosage and Administration Information

How to Use Scopamin Plus — Administration Guidelines

The administration of Scopamin Plus, a fixed-dose combination product containing Hyoscine Butylbromide 10 mg and Acetaminophen 500 mg, is governed by specific parameters outlined in prescribing information. These guidelines define the standardized route, dosage limits, and maximum permitted treatment duration.

Administration Scope

Feature	Guideline
Route of administration:	Oral use only.
Dosing schedule:	1 to 2 tablets per dose, taken up to 3 times daily.
Maximum Daily Limit:	Intake must not exceed 6 tablets in any 24-hour period.
Preparation:	Tablets must be swallowed whole with adequate liquid and are not to be crushed or broken.
Age-group rules:	Adults and adolescents 10 years and older follow the standard dose; the product is not suitable for children under 10 years of age.

Instruction Classifications

Classification	Pattern
Administration method type:	Oral
Frequency pattern:	3 times daily
Use-context constraints:	Short-term use only

Resulting Procedural Structure

Step sequence:

Take 1 to 2 tablets per dose.
Swallow the tablet(s) whole with an adequate amount of liquid.
Repeat the dose up to 3 times daily, strictly observing the 6 tablet maximum.
Limit use to a maximum of 3 days unless otherwise instructed.

Connection to the overall use protocol: This protocol establishes the standardized use of the medicine as a brief course of action, clearly defining both the required oral route and a strict controlled frequency that must not exceed the defined daily maximum. The instructions are designed to regulate the product's application to short-term needs and mandate the proper method of ingestion by requiring the tablet to be swallowed intact.

Recent Clinical Evidence

Research evidence / Overview of studies

Overview of Efficacy and Safety

Research has explored whether joint function may be affected and examined the time-course of pain changes in patients with mild to moderate osteoarthritis (OA). Clinical trials have generally centered on the drug's short-term effects, and the focus of research has been less on long-term outcomes. The evidence base has been evaluated by researchers concerning pain management in OA.

Studies have evaluated the drug’s relation to the severity of inflammation and explored its potential role in preventing cartilage degradation. The drug has been a subject of research and its safety profile has been evaluated in study populations.

Clinical Findings on Combination Therapy

Research examining a combination of the two agents has evaluated whether there are changes in swelling and whether the combination may relate to changes in pain and stiffness. This combination was the subject of research examining OA symptoms.

Studies have evaluated the relation between the combination and the use of non-steroidal anti-inflammatory drugs (NSAIDs) during the period of research. The majority of studies reviewed by researchers focused on patients with confirmed diagnosis of knee OA. Research has investigated the timeframe for observed changes, with most studies reporting results after 6-8 weeks of evaluation.

Pharmacokinetics and Administration

Research has examined whether taking the drug in the evening may relate to absorption rates, and explored its uptake when taken with a light meal. Research measured the drug's half-life in plasma in adult volunteers, finding it to be approximately 10 hours.

Drug Interactions

Studies have explored the potential for interactions when this treatment is combined with high-dose blood thinners, particularly related to bleeding parameters. Additional research has evaluated the potential for drug interactions with common anti-diabetic medications, with results that varied across trials.

Frequently Asked Questions (FAQ)

Common questions about Scopamin Plus (FAQ)

Q: What specific types of cramps or spasms is Scopamin Plus typically used for?

A: Official indications for the product state it is intended to address spasmodic pain in several systems. This includes cramping pain in gastrointestinal conditions, the biliary tract, the lower urinary tract, and pain related to the female genital system, such as in dysmenorrhea (menstrual cramps).

Q: Is Scopamin Plus meant for short-term or long-term use?

A: Regulatory documents state that this medicine is intended for a short duration of use only. Official guidelines specify that the product is for short-term use and intake is typically limited to a maximum of three days. This constraint is due to the potential risks associated with prolonged use of the combination's ingredients.

Q: Does Scopamin Plus treat general stomach pain or only pain from muscle spasms?

A: The product's general purpose is targeted relief for acute spasmodic pain, meaning it is indicated for pain that arises specifically from involuntary muscle contraction or spasms, rather than general, non-spasm-related abdominal discomfort.

Q: Is the mechanism of action of Scopamin Plus known to affect the central nervous system?

A: The product's two components act differently in the body. The analgesic (pain relief) component, Acetaminophen, works predominantly within the Central Nervous System (CNS). However, the antispasmodic component, Hyoscine Butylbromide, is designed to act peripherally and is generally described as not passing the blood-brain barrier, which minimizes central nervous system effects from that ingredient.

Q: Are dizziness and drowsiness common side effects when using Scopamin Plus?

A: Regulatory documents classify drowsiness as a possible side effect associated with the anticholinergic component. Official safety information notes that caution is necessary when engaging in activities that require mental alertness until the drug's effect is fully known.

Q: Is it safe to consume alcohol while taking Scopamin Plus?

A: Official label warnings indicate that the risk of severe liver damage (hepatotoxicity) from the Acetaminophen component is significantly increased when combined with chronic, excessive consumption of alcohol. This increased risk of toxicity is officially documented in relation to chronic, excessive consumption of alcohol (e.g., three or more drinks per day).

Q: Does Scopamin Plus interact with any common over-the-counter pain relievers?

A: Concomitant use of any other medicine containing Acetaminophen is strictly prohibited to avoid toxicity. Official documents indicate that caution is necessary when co-administering with other NSAIDs (Non-Steroidal Anti-inflammatory Drugs) due to the potential for additive adverse reactions.

Q: What organs (like the liver or kidneys) are most important to monitor while using Scopamin Plus?

A: Regulatory documents state that caution is necessary for individuals with impaired hepatic (liver) or renal (kidney) function. The official safety constraints state that the blood count and organ function may require monitoring when this product is used for prolonged periods.

Q: Is Scopamin Plus generally suitable for use by children?

A: Official guidelines state that the product is generally not suitable for children under 10 years of age. Use in younger populations is restricted because the safety and efficacy of the combination product have not been fully established in those age groups.

Q: Is there specific guidance for elderly patients regarding the use of Scopamin Plus?

A: Regulatory guidance for this class of anticholinergic agent notes that elderly patients are more susceptible to CNS adverse effects, such as confusion. Official guidance notes that use in this population may necessitate closer monitoring and potentially lower doses to minimize adverse effects.

Q: Are there specific warnings about using Scopamin Plus during pregnancy or breastfeeding?

A: The medicine is generally not recommended or may be considered unsafe during pregnancy due to insufficient safety data. However, official regulatory documents describe the product as generally safe to use during lactation.

Q: How long does it typically take for a person to feel the effects of Scopamin Plus? (Onset)

A: Based on real-world patient surveys examining relief for spasmodic pain, the onset of symptom relief was reported to be within 60 minutes for the majority of participants. This timeframe reflects how quickly the medicine begins to act in the body.

Q: What is the expected duration of effect after taking a dose of Scopamin Plus?

A: Pharmacokinetic research measured the drug's half-life in adult volunteers to be approximately 10 hours. The half-life is the time it takes for the concentration of the medicine in the blood to decrease by half, and this figure is directly related to the expected duration of the therapeutic effect.

Q: Is this medication effective for symptoms of irritable bowel syndrome (IBS)?

A: The combination product is approved for spasmodic pain in general gastrointestinal conditions. Regulatory-sourced clinical surveys have evaluated its use and reported relief for gastrointestinal cramps and pain in patients who cite IBS as a cardinal symptom.

Q: Is the 'Scopamin' part of the drug the same as scopolamine or hyoscine?

A: The antispasmodic component of the medicine is Hyoscine Butylbromide. This chemical is a semi-synthetic derivative of the naturally occurring alkaloid Hyoscine, which is also known by the name Scopolamine.

Q: How is the effect of Scopamin Plus described at a high level?

A: The medicine is defined as an Antispasmodic-Analgesic Combination for the purpose of targeted relief by managing both the underlying muscle spasm and the accompanying pain.

Q: Does Scopamin Plus have a known risk of causing confusion, especially in older adults?

A: As an anticholinergic agent, the drug class has a documented risk of causing certain CNS adverse effects, which can include confusion. Official guidance notes that this specific risk is known to be increased in elderly patients.

Q: Is there a potential for withdrawal symptoms after stopping Scopamin Plus?

A: Regulatory information for this drug class notes that withdrawal symptoms may occur after discontinuation, particularly if the medicine was used frequently or for a longer duration. These potential symptoms can include dizziness, nausea, headache, and mental confusion.

Q: Does Scopamin Plus affect the ability to sweat or regulate body temperature?

A: Regulatory documents list dyshidrosis (abnormal sweating) as an uncommon adverse reaction, which is a known anticholinergic effect. Flushings are also listed as an anticholinergic side effect.

Q: What should a patient know about using Scopamin Plus before having an MRI?

A: The Hyoscine Butylbromide component of this medicine is sometimes used during abdominal or pelvic MRI and other imaging procedures. It is used to reduce the involuntary movement of internal organs, which helps to improve the quality of the image.

Q: Is it normal to feel disoriented if I participate in activities like water sports while using this drug?

A: Official safety documents list potential side effects including dizziness, drowsiness, and visual disturbances, which necessitate caution when performing activities that require mental alertness.

Q: Is there evidence about the effectiveness of Scopamin Plus compared to placebo in clinical trials?

A: Official research reviews indicate that the components have demonstrated efficacy in controlled trials when compared with a placebo (an inactive substance) for their respective approved indications.

Q: Has the drug been studied for treating other types of pain besides abdominal spasms?

A: Yes, research has extended beyond spasmodic pain relief. Studies have examined the time-course of pain changes and evaluated the drug’s relation to inflammation in patients with mild to moderate osteoarthritis (OA).

How should Scopamin Plus be stored and disposed of?

How to Store and Dispose of Scopamin Plus?

Official regulatory documents define strict conditions for the storage and disposal of Scopamin Plus to maintain stability and ensure safety.

Storage Conditions

Condition	Requirement
Temperature	Store below 30°C (thirty degrees Celsius).
Protection	Must be protected from light and stored in a dry location.
Handling	Keep the medicine out of the sight and reach of children.

These storage requirements are essential to maintain the integrity of the tablet and its active ingredients.

Disposal Instructions

Unused or expired Scopamin Plus must not be disposed of by flushing it down a toilet or mixing it with household trash. The product should be discarded according to local regulations for pharmaceutical waste, following official community or pharmacy take-back programs.

Scopamin Plus